Daniel M. Junius

Retired President and Chief Executive Officer, ImmunoGen, Inc.

Independent Director

Age: 71

Director since:
March 2014

Audit (Chair)

Other current public company director service:

  • GlycoMimetics, Inc. (since Mar. 2016)

Former public company director service:

  • ImmunoGen, Inc. (Nov. 2008 – Jun. 2018)
  • Vitae Pharmaceuticals, Inc. (Jul. 2016 – Oct. 2016)


ImmunoGen, Inc.

  • President and Chief Executive Officer (2009 – 2016)
  • President and Chief Operating Officer and Acting Chief Financial Officer (July 2008 - December 2008)
  • Executive Vice President and Chief Financial Officer (2006 – 2008)
  • Senior Vice President and Chief Financial Officer (2005 – 2006)

New England Business Service, Inc.

  • Executive Vice President and Chief Financial Officer (2002 – 2004)
  • Senior Vice President and Chief Financial Officer (1998 – 2002)

Nashua Corporation

  • Vice President and Chief Financial Officer (1996 – 1998)
  • Joined in 1984 and held various financial management positions of increasing responsibility


  • Financial Acumen: Substantial knowledge and experience in the review and preparation of financial statements and a strong understanding of complex financial and accounting topics, internal controls over financial reporting, and financial planning developed over the course of his almost 25 years serving in various financial management roles, including more than a decade as the chief financial officer of various companies.
  • Science, Technology and R&D: Experience gained as the former Chief Executive Officer and Chief Financial Officer of ImmunoGen, Inc., a then public biotechnology company, which was acquired by AbbVie Inc. in February 2024, that developed targeted anticancer therapeutics, where he was credited with expanding the company’s technology portfolio significantly, as well as from his board service overseeing multiple biotechnology companies.
  • Corporate Strategy: Deep experience as displayed while at ImmunoGen, Inc., where under his leadership the company transformed from being a research-focused company to one with strong clinical development and manufacturing capabilities.
  • Risk Oversight: Extensive experience identifying, assessing and managing enterprise-level risk through over 10 years of experience as a public company senior executive and service on numerous public company boards.
  • Mr. Junius also brings significant executive leadership, corporate governance, human capital management, operations and corporate finance skills and experience to the Board.


  • BA, Political Science, Boston College
  • MA, Management, Northwestern University’s Kellogg School of Management